Home/Filings/4/0001209191-22-048471
4//SEC Filing

Nabulsi Azmi 4

Accession 0001209191-22-048471

CIK 0001783183other

Filed

Sep 1, 8:00 PM ET

Accepted

Sep 2, 4:05 PM ET

Size

6.8 KB

Accession

0001209191-22-048471

Insider Transaction Report

Form 4
Period: 2022-09-01
Nabulsi Azmi
Chief Operating Officer
Transactions
  • Award

    Common Stock

    2022-09-01+7,50041,971 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    2,355.22
  • Common Stock

    (indirect: By Trust)
    785,700
Footnotes (3)
  • [F1]Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  • [F2]Includes 1,093 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022.
  • [F3]Includes 1,511.80 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.

Issuer

Phathom Pharmaceuticals, Inc.

CIK 0001783183

Entity typeother

Related Parties

1
  • filerCIK 0001791412

Filing Metadata

Form type
4
Filed
Sep 1, 8:00 PM ET
Accepted
Sep 2, 4:05 PM ET
Size
6.8 KB